[2019] To find out why the committee made the 2019 recommendations on the assessment of proteinuria and how they might affect practice, see rationale and impact. 1.3 Management of chronic hypertension in pregnancy Pre-pregnancy advice 1.3.1 Offer women with chronic hypertension referral to a specialist in hypertensive disorders of pregnancy to discuss the risks and benefits of 1.3.2 Advise women who take angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers[2] (ARBs): that there is an increased risk of congenital abnormalities if these drugs are taken during pregnancy to discuss alternative antihypertensive treatment with the healthcare professional responsible for managing their hypertension, if they are planning pregnancy to discuss alternative treatment with the healthcare professional responsible for managing their condition, if ACE inhibitors or ARBs are being taken for other conditions such as renal disease. [2010, amended 2019] 1.3.3 Stop antihypertensive treatment in women taking ACE inhibitors or ARBs if they become pregnant (preferably within 2 working days of notification of pregnancy) and offer alternatives. [2010] 1.3.4 Advise women who take thiazide or thiazide-like diuretics: that there may be an increased risk of congenital abnormalities and neonatal complications if these drugs are taken during pregnancy to discuss alternative antihypertensive treatment with the healthcare professional responsible for managing their hypertension, if they are planning 1.3.5 Advise women who take antihypertensive treatments other than ACE inhibitors, ARBs, thiazide or thiazide-like diuretics that the limited evidence available has not shown an increased risk of congenital malformation with such treatments. [2010, amended 2019] Treatment of chronic hypertension 1.3.6 Offer pregnant women with chronic hypertension advice on: weight management exercise healthy eating lowering the amount of salt in their diet. Provide this advice in line with the NICE guideline on hypertension in adults. 